(NASDAQ:RZLT), Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage […]

DUBAI, United Arab Emirates, Jan. 07, 2026 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) has reported a 300% increase in its token price across Presale stages since the Presale began in early 2025. The project, which is building a decentralized lending and borrowing protocol, says the token has moved from $0.01 in Phase 1 to $0.04

(NasdaqGM:RAPP), U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial

Mahe, Seychelles, Jan. 07, 2026 (GLOBE NEWSWIRE) — BitMart, a trusted global digital asset service provider, today announced its official partnership with CryptoKnights, the world's first reality-TV show centered on blockchain entrepreneurship. Through this landmark collaboration, BitMart CEO Nathan (Nenter) Chow will join Season 2's prestigious judging panel in several episodes of the season, bringing

(NasdaqGM:GANX), BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”)

(NASDAQ:GLUE), In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values

(TSX:ABX),(NYSE:B),(LSE:0R22), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) will release its full year and fourth quarter 2025 results before markets open on Thursday, February 5, 2026 at 6:00 AM ET. The management team will host a live webcast and presentation at 11:00 AM ET the same day, followed by a question-and-answer

(TSX-V:NBLC),(OTC US:NBTRF),(Other OTC:NBTRF), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX – V: NBLC) (the “Company” or “Nobel”) is pleased to announce commencement of mobilization by the Company's diamond drill contractor to the Cuprita copper project (“Cuprita” or the “Project”) and drilling will commence during the week of January 12th. All necessary

(NASDAQ:BTAI), NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration's (FDA) approval of IGALMI(R)

(TSX-V:EMO),(OTC US:EMOTF),(Other OTC:EMOTF),(Frankfurt:LLJA), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports results from ongoing drilling of El Cura deposit. El Cura is part of Emerita's wholly owned Iberian Belt West project (“IBW” or the “Project”; Figure 1) which hosts three Volcanogenic Massive